DCGI authorizes Bharat Biotech’s intranasal Covid-19 vaccine for emergency use
Bharat Biotech's Intranasal vaccine
New Delhi: The Bharat Biotech on Tuesday got emergency use authorization from the Drugs Controller General of India (DCGI) for the Intranasal Covid-19 vaccine.
This will be India's first nasal vaccine for COVID-19. Union Minister of Health and Family Welfare Mansukh Mandaviya termed it a 'Big boost' to India's fight against Covid-19.
He took to Twitter and said, "Big Boost to India's Fight Against COVID-19! Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation."
"This step will further strengthen our collective fight against the pandemic. India has harnessed its science, R&D, and human resources in the fight against COVID-19 under PM @NarendraModi Ji's leadership," he added.
He also said that we will defeat Covid-19 with a science-driven approach. "With the science-driven approach and Sabka Prayas, we will defeat COVID-19," he said.
Get Breaking News First and Latest Updates from India and around the world
on News24. Follow News24 and Download our - News24
Android App. Follow News24 on Facebook, Telegram, Google
News.